SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Medicamen Biotech - Quaterly Results

28 May 2026 Evaluate
An increase of about 110.35% to Rs. 546.81 millions in the total revenue was observed for the quarter ended March 2026. The total revenue was pegged at Rs. 259.95 millions during the similar quarter previous year.Net profit stood at Rs. 29.73  millions  compared to Rs. 24.10 millions in the corresponding previous quarter,high by 23.36%.The company reported a good operating profit of 58.54 millions compared to 41.26 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 546.81 259.95 110.35 1788.46 1514.63 18.08 1788.46 1514.63 18.08
Other Income 17.26 52.20 -66.93 31.04 62.25 -50.14 31.04 62.25 -50.14
PBIDT 58.54 41.26 41.88 213.90 227.83 -6.11 213.90 227.83 -6.11
Interest 5.99 6.23 -3.85 27.84 30.45 -8.57 27.84 30.45 -8.57
PBDT 52.55 35.03 50.01 186.06 197.38 -5.74 186.06 197.38 -5.74
Depreciation 17.25 4.66 270.17 70.59 69.62 1.39 70.59 69.62 1.39
PBT 35.30 30.37 16.23 115.47 127.76 -9.62 115.47 127.76 -9.62
TAX 5.57 6.27 -11.16 21.39 33.27 -35.71 21.39 33.27 -35.71
Deferred Tax -0.95 -0.99 -4.04 -4.09 -3.12 31.09 -4.09 -3.12 31.09
PAT 29.73 24.10 23.36 94.08 94.49 -0.43 94.08 94.49 -0.43
Equity 135.63 127.15 6.67 135.63 127.15 6.67 135.63 127.15 6.67
PBIDTM(%) 10.71 15.87 -32.55 11.96 15.04 -20.49 11.96 15.04 -20.49

Medicamen Biotech Share Price

257.95 2.45 (0.96%)
05-Jun-2026 10:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1789.25
Dr. Reddys Lab 1274.20
Cipla 1387.50
Zydus Lifesciences 1088.05
Lupin 2266.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×